Market closed
Enanta/$ENTA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Enanta
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
Ticker
$ENTA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
131
Website
Enanta Metrics
BasicAdvanced
$106M
-
-$5.48
0.49
-
Price and volume
Market cap
$106M
Beta
0.49
52-week high
$17.80
52-week low
$4.71
Average daily volume
638K
Financial strength
Current ratio
5.212
Quick ratio
4.985
Long term debt to equity
147.555
Total debt to equity
175.492
Interest coverage (TTM)
-11.12%
Management effectiveness
Return on assets (TTM)
-18.13%
Return on equity (TTM)
-67.17%
Valuation
Price to revenue (TTM)
1.558
Price to book
0.82
Price to tangible book (TTM)
0.82
Price to free cash flow (TTM)
-1.089
Growth
Revenue change (TTM)
-14.61%
Earnings per share change (TTM)
-14.05%
3-year revenue growth (CAGR)
-11.35%
3-year earnings per share growth (CAGR)
11.88%
What the Analysts think about Enanta
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Enanta stock.
Enanta Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Enanta Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Enanta News
AllArticlesVideos
Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)
Business Wire·2 months ago
Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV)
Business Wire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Enanta stock?
Enanta (ENTA) has a market cap of $106M as of January 31, 2025.
What is the P/E ratio for Enanta stock?
The price to earnings (P/E) ratio for Enanta (ENTA) stock is 0 as of January 31, 2025.
Does Enanta stock pay dividends?
No, Enanta (ENTA) stock does not pay dividends to its shareholders as of January 31, 2025.
When is the next Enanta dividend payment date?
Enanta (ENTA) stock does not pay dividends to its shareholders.
What is the beta indicator for Enanta?
Enanta (ENTA) has a beta rating of 0.49. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.